



Emerging Therapies Workgroup

June 22, 2020

Welcome

Today's Meeting

▶ GoTo meeting instructions:

- ▶ Please mute when you're not talking
- ▶ If possible, please turn your webcam on when you're ready to talk
- ▶ Use the Chat Box for any comments or questions

Review of Agenda

Agenda

- ▶ Welcome and Roll Call
- ▶ Meeting expectations
- ▶ Options for drug coverage policy makers when there is a lack of evidence
- ▶ BREAK
- ▶ Tracking outcomes: Patient registry, Provider registry
- ▶ Workgroup discussion
- ▶ Workgroup wrap up

Cody Gillenwater	Stephanie Simpson	Jean-Baptiste Rouillet
Carly Rodriguez	Melissa Tribelhorn	Sean Sullivan
Bruce Wilson	Jonathan Espenschied	Monica Thakar
Shawn Akavan	Armen Khatchatourian	Donna Sullivan
Petra Eichelsdoerfer	Thomas May	Robyn Williams
Shea Wilson	Rebecca Owen	Judy Zerzan
Kerrie Fowler	Yusuf Rashid	Mike Bonetto
Foxy Williams	Valerie King	John Vassall
	Vivienne Souter	Kristin Sitcov

Workgroup's Scope

Issues related to Emerging Therapies:

- ▶ Long-term funding
- ▶ Quality oversight and outcome tracking
- ▶ Management of patients eligible for emerging therapies
- ▶ Potential improvements to health outcomes and quality of life
- ▶ Potential long-term savings or expenditures to the state
- ▶ Metrics that could be used to measure the fiscal and health impacts

Schedule

▶ June 18, 2019 – Spokane

- ▶ Overview of new therapies coming to market
- ▶ Private sector perspective on managing emerging therapies
- ▶ HCA/Medicaid perspective on managing emerging therapies
- ▶ Current financing

▶ October 18, 2019- Olympia

- ▶ Patient decision aids
- ▶ Patient experience
- ▶ Patient advocates present


▶ February 19, 2020- SeaTac

- ▶ Long-term funding for emerging therapies
- ▶ Potential funding options between manufacturers and the state
- ▶ Different payment options between the state and managed care organizations

▶ June 22, 2020 – GoTo Meeting

- ▶ Quality oversight and outcome tracking of providers and facilities administering emerging therapies
- ▶ Potential improvements and harms to health outcomes and quality of life for patients
- ▶ Metrics that could be used to measure the fiscal and health impacts of emerging therapies

Decisions are Complex and Affected by Perspective



- ▶ What the decision-makers value and how they value it is a complex inter-relationship of what matters within the organization and who they serve.
- ▶ The decision-making criteria are shared though elements of it may be weighted or valued differently.

Henshall, C. Schuller, T., **Health Technology Assessment, Value-based Decision Making and Innovation.**, International Journal of Technology Assessment in Health Care, 29:4 (2013), 353-359.

HCA's Thoughts and Reflections

Meeting expectations